• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Microbiol Immunol Infect . Long term SARS-CoV-2-specific cellular immunity after COVID-19 in liver transplant recipients

tetano

Editor, Senior Moderator
J Microbiol Immunol Infect


. 2023 Mar 17;S1684-1182(23)00071-3.
doi: 10.1016/j.jmii.2023.03.003. Online ahead of print.
Long term SARS-CoV-2-specific cellular immunity after COVID-19 in liver transplant recipients


Maria J Citores[SUP] 1 [/SUP], Aranzazu Caballero-Marcos[SUP] 2 [/SUP], Valentín Cuervas-Mons[SUP] 3 [/SUP], Roberto Alonso-Fernández[SUP] 4 [/SUP], Javier Graus-Morales[SUP] 5 [/SUP], Ana Arias-Milla[SUP] 6 [/SUP], Maricela Valerio[SUP] 7 [/SUP], Patricia Muñoz[SUP] 8 [/SUP], Magdalena Salcedo[SUP] 9 [/SUP]



Affiliations
Free PMC article

Abstract

Purpose: Long-term immunity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in immunosuppressed patients is not well characterized. We aimed to explore the long-term natural immunity against SARS-CoV-2 in liver transplant (LT) recipients compared to the non-transplanted population (control group).
Methods: Fifteen LT recipients and 15 controls matched according to variables associated with disease severity were included at 12 months following the coronavirus disease 2019 (COVID-19) onset. Peripheral blood mononuclear cells were stimulated with peptide pools covering spike (S), nucleocapside (N), and membrane (M) proteins. Reactive CD4+ and CD8+ T cells were identified using flow cytometry, and cytokine production was evaluated in the culture supernatants using cytometric bead array. Serum anti-N and anti-S IgG antibodies were detected with chemiluminescence.
Results: The percentage of patients with a positive response in both CD4+ and CD8+ T cells against each viral protein and IL2, IL10, TNF-α, and IFN-γ levels was similar between LT recipients and controls. IFN-γ levels were positively correlated with the percentage of reactive CD4+ (p = 0.022) and CD8+ (p = 0.043) T cells to a mixture of M + N + S peptide pools. The prevalence and levels of anti-N and anti-S IgG antibodies were slightly lower in the LT recipients, but the difference was not statistically significant.
Conclusion: LT recipients exhibited a similar T cell response compared to non-transplanted individuals one year after COVID-19 diagnosis.

Keywords: Flow cytometry; Humoral immunity; Liver transplantation; Reactive T cells; SARS-CoV-2.
 
Back
Top Bottom